Risk factors for bloodstream infection with Klebsiella pneumoniae producing VIM-1 metallo-β-lactamase

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 4, 2010, Pages 784-788

  Daikos, George L ^a   Vryonis, Evangelos ^b   Psichogiou, Mina ^a   Tzouvelekis, Leonidas S ^a   Liatis, Stavros ^a   Petrikkos, Panayiotis ^a   Kosmidis, Chris ^a   Tassios, Panayotis T ^a   Bamias, Giorgos ^a   Skoutelis, Athanasios ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Carbapenem resistance; Carbapenemases; Enterobacteriaceae

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; METALLO BETA LACTAMASE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; BETA LACTAMASE; VIM 1 METALLO BETA LACTAMASE; VIM-1 METALLO-BETA-LACTAMASE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; CONTROLLED STUDY; ENZYME SYNTHESIS; FEMALE; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RISK FACTOR; TERTIARY HEALTH CARE; UNIVARIATE ANALYSIS; BACTEREMIA; BIOSYNTHESIS; HOSPITAL; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAMASES; FEMALE; HOSPITALS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 77952567322     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq005     Document Type: Article

References (13)

1. Walsh TR, Toleman MA, Poirel L et al. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
2. VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 2008; 61: 59-63.
3. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53: 1868-73.
4. Friedman ND, Kaye KS, Stout JE et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-7.
5. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-40.
6. McCabe W, Jackson G. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110: 847-55.
7. Kwak YG, Choi SH, Choo EJ et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae infection among hospitalised patients. Microb Drug Resist 2005; 11: 165-9.
8. Patel G, Hupricar S, Factor SH et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-106.
9. Hussein K, Sprecher H, Mashiach T et al. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics and susceptibility patterns. Infect Control Hosp Epidemiol 2009; 30: 666-71.
10. Falagas M, Rafailidis P, Kofteridis D et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case-control study. J Antimicrob Chemother 2007; 60: 1124-30.
11. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52: 1028-33.
12. Ben Ami R, Schwaber MJ, Navon-Venezia S et al. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42: 935-7.
13. Harris AD, Tobi B, Carmeli Y et al. Methodological principles of case-control studies that analysed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32: 1055-61.